Pharmacodynamic Biomarker Testing-Global Market Status and Trend Report 2016-2026

Table of Contents

Chapter 1 Overview of Pharmacodynamic Biomarker Testing

• 1.1 Definition of Pharmacodynamic Biomarker Testing in This Report
• 1.2 Commercial Types of Pharmacodynamic Biomarker Testing
  • 1.2.1 LC-MS
  • 1.2.2 MS
• 1.3 Downstream Application of Pharmacodynamic Biomarker Testing
  • 1.3.1 Hospital
  • 1.3.2 Diagnostic Center
  • 1.3.3 Others
• 1.4 Development History of Pharmacodynamic Biomarker Testing
• 1.5 Market Status and Trend of Pharmacodynamic Biomarker Testing 2016-2026
  • 1.5.1 Global Pharmacodynamic Biomarker Testing Market Status and Trend 2016-2026
  • 1.5.2 Regional Pharmacodynamic Biomarker Testing Market Status and Trend 2016-2026

Chapter 2 Global Market Status and Forecast by Regions

• 2.1 Market Development of Pharmacodynamic Biomarker Testing 2016-2021
• 2.2 Production Market of Pharmacodynamic Biomarker Testing by Regions
  • 2.2.1 Production Volume of Pharmacodynamic Biomarker Testing by Regions
  • 2.2.2 Production Value of Pharmacodynamic Biomarker Testing by Regions
• 2.3 Demand Market of Pharmacodynamic Biomarker Testing by Regions
• 2.4 Production and Demand Status of Pharmacodynamic Biomarker Testing by Regions
  • 2.4.1 Production and Demand Status of Pharmacodynamic Biomarker Testing by Regions 2016-2021
  • 2.4.2 Import and Export Status of Pharmacodynamic Biomarker Testing by Regions 2016-2021

Chapter 3 Global Market Status and Forecast by Types

• 3.1 Production Volume of Pharmacodynamic Biomarker Testing by Types
• 3.2 Production Value of Pharmacodynamic Biomarker Testing by Types
• 3.3 Market Forecast of Pharmacodynamic Biomarker Testing by Types

Chapter 4 Global Market Status and Forecast by Downstream Industry

• 4.1 Demand Volume of Pharmacodynamic Biomarker Testing by Downstream Industry
• 4.2 Market Forecast of Pharmacodynamic Biomarker Testing by Downstream Industry

Chapter 5 Market Driving Factor Analysis of Pharmacodynamic Biomarker Testing

• 5.1 Global Economy Situation and Trend Overview
• 5.2 Pharmacodynamic Biomarker Testing Downstream Industry Situation and Trend Overview

Chapter 6 Pharmacodynamic Biomarker Testing Market Competition Status by Major Manufacturers

• 6.1 Production Volume of Pharmacodynamic Biomarker Testing by Major Manufacturers
• 6.2 Production Value of Pharmacodynamic Biomarker Testing by Major Manufacturers
• 6.3 Basic Information of Pharmacodynamic Biomarker Testing by Major Manufacturers
  • 6.3.1 Headquarters Location and Established Time of Pharmacodynamic Biomarker Testing Major Manufacturer
  • 6.3.2 Employees and Revenue Level of Pharmacodynamic Biomarker Testing Major Manufacturer
• 6.4 Market Competition News and Trend
  • 6.4.1 Merger, Consolidation or Acquisition News
  • 6.4.2 Investment or Disinvestment News
  • 6.4.3 New Product Development and Launch

Chapter 7 Pharmacodynamic Biomarker Testing Major Manufacturers Introduction and Market Data

• 7.1 Almac
  • 7.1.1 Company profile
  • 7.1.2 Representative Pharmacodynamic Biomarker Testing Product
  • 7.1.3 Pharmacodynamic Biomarker Testing Sales, Revenue, Price and Gross Margin of Almac
• 7.2 ACM Global Laboratories
  • 7.2.1 Company profile
  • 7.2.2 Representative Pharmacodynamic Biomarker Testing Product
  • 7.2.3 Pharmacodynamic Biomarker Testing Sales, Revenue, Price and Gross Margin of ACM Global Laboratories
• 7.3 Charles River
  • 7.3.1 Company profile
  • 7.3.2 Representative Pharmacodynamic Biomarker Testing Product
  • 7.3.3 Pharmacodynamic Biomarker Testing Sales, Revenue, Price and Gross Margin of Charles River
• 7.4 Agilent
  • 7.4.1 Company profile
  • 7.4.2 Representative Pharmacodynamic Biomarker Testing Product
  • 7.4.3 Pharmacodynamic Biomarker Testing Sales, Revenue, Price and Gross Margin of Agilent
• 7.5 Sygnature Discovery
  • 7.5.1 Company profile
  • 7.5.2 Representative Pharmacodynamic Biomarker Testing Product
  • 7.5.3 Pharmacodynamic Biomarker Testing Sales, Revenue, Price and Gross Margin of Sygnature Discovery
• 7.6 Myriad RBM
  • 7.6.1 Company profile
  • 7.6.2 Representative Pharmacodynamic Biomarker Testing Product
  • 7.6.3 Pharmacodynamic Biomarker Testing Sales, Revenue, Price and Gross Margin of Myriad RBM
• 7.7 AstraZeneca
  • 7.7.1 Company profile
  • 7.7.2 Representative Pharmacodynamic Biomarker Testing Product
  • 7.7.3 Pharmacodynamic Biomarker Testing Sales, Revenue, Price and Gross Margin of AstraZeneca
• 7.8 BioAgilytix Labs
  • 7.8.1 Company profile
  • 7.8.2 Representative Pharmacodynamic Biomarker Testing Product
  • 7.8.3 Pharmacodynamic Biomarker Testing Sales, Revenue, Price and Gross Margin of BioAgilytix Labs
• 7.9 Merck
  • 7.9.1 Company profile
  • 7.9.2 Representative Pharmacodynamic Biomarker Testing Product
  • 7.9.3 Pharmacodynamic Biomarker Testing Sales, Revenue, Price and Gross Margin of Merck

Chapter 8 Upstream and Downstream Market Analysis of Pharmacodynamic Biomarker Testing

• 8.1 Industry Chain of Pharmacodynamic Biomarker Testing
• 8.2 Upstream Market and Representative Companies Analysis
• 8.3 Downstream Market and Representative Companies Analysis

Chapter 9 Cost and Gross Margin Analysis of Pharmacodynamic Biomarker Testing

• 9.1 Cost Structure Analysis of Pharmacodynamic Biomarker Testing
• 9.2 Raw Materials Cost Analysis of Pharmacodynamic Biomarker Testing
• 9.3 Labor Cost Analysis of Pharmacodynamic Biomarker Testing
• 9.4 Manufacturing Expenses Analysis of Pharmacodynamic Biomarker Testing

Chapter 10 Marketing Status Analysis of Pharmacodynamic Biomarker Testing

• 10.1 Marketing Channel
  • 10.1.1 Direct Marketing
  • 10.1.2 Indirect Marketing
  • 10.1.3 Marketing Channel Development Trend
• 10.2 Market Positioning
  • 10.2.1 Pricing Strategy
  • 10.2.2 Brand Strategy
  • 10.2.3 Target Client
• 10.3 Distributors/Traders List

Chapter 11 Report Conclusion

Chapter 12 Research Methodology and Reference

• 12.1 Methodology/Research Approach
  • 12.1.1 Research Programs/Design
  • 12.1.2 Market Size Estimation
  • 12.1.3 Market Breakdown and Data Triangulation
• 12.2 Data Source
  • 12.2.1 Secondary Sources
  • 12.2.2 Primary Sources